We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+38.56%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$47.5M
(+26%)
Cap. Flow
-$5.93M
Cap. Flow
% of AUM
-2.6%
Top 10 Holdings %
Top 10 Hldgs %
58.57%
Holding
49
New
15
Increased
12
Reduced
11
Closed
11
Avg Time Held Equity + Options
2.7
quarters
Top 10 Avg Time Held Equity + Options
2.2
quarters
Top 20 Avg Time Held Equity + Options
2.8
quarters
Avg Time Held Equity only
3
quarters
Top 10 Avg Time Held Equity only
2.2
quarters
Top 20 Avg Time Held Equity only
2.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$7.8M |
| 2 |
AnaptysBio
ANAB
|
+$5.55M |
| 3 |
Envista
NVST
|
+$4.69M |
| 4 |
Organogenesis Holdings
ORGO
|
+$3.92M |
| 5 |
Aldeyra Therapeutics
ALDX
|
+$3.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$17M |
| 2 |
HNGR
Hanger Inc.
HNGR
|
+$8.05M |
| 3 |
uniQure
QURE
|
+$5.02M |
| 4 |
Humana
HUM
|
+$3.07M |
| 5 |
AbbVie
ABBV
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.18% |
| 2 | Miscellaneous | 3.98% |
| 3 | Industrials | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$17.4B
| $19.5M | 8.54% |
133,900
+2,060
| +2% | +$284K |
2018 Q3
5 quarters
|
|
|
2
uniQure
QURE
$1.47B
| $17M | 7.47% |
237,500
-91,478
| -28% | -$5.02M |
2019 Q2
2 quarters
|
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.9M | 6.54% |
328,129
+164,996
| +101% | +$7.8M |
2018 Q1
7 quarters
|
|
4
Kura Oncology
KURA
$865M
| $14.2M | 6.25% |
1,036,000
+147,848
| +17% | +$2.19M |
2018 Q2
6 quarters
|
|
5
United Therapeutics
UTHR
$23.2B
| $14.2M | 6.23% |
161,195
+28,258
| +21% | +$2.49M |
2019 Q2
2 quarters
|
|
|
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.9M | 5.65% |
62,900
+309
| +0.5% | +$56.4K |
2017 Q4
8 quarters
|
|
7
Iovance Biotherapeutics
IOVA
$6.51B
| $10.8M | 4.72% |
388,600
+42,451
| +12% | +$966K |
2017 Q4
8 quarters
|
|
8
AC Immune
ACIU
$240M
| $10.6M | 4.65% |
1,242,843
-5,610
| -0.4% | -$37.4K |
2019 Q1
3 quarters
|
|
9
MeiraGTx Holdings
MGTX
$936M
| $10.4M | 4.55% |
517,844
+179,748
| +53% | +$3.08M |
2019 Q3
1 quarter
|
|
|
ARQL
10
DELISTED
Arqule Inc
ARQL
| $8.99M | 3.95% |
450,326
+85,529
| +23% | +$992K |
2019 Q2
2 quarters
|
|
11
Centene
CNC
$34.2B
| $8.98M | 3.94% |
142,800
-22,200
| -13% | -$1.2M |
2017 Q4
8 quarters
|
|
|
12
Aldeyra Therapeutics
ALDX
$52.3M
| $8.3M | 3.64% |
1,428,277
+638,049
| +81% | +$3.69M |
2018 Q4
4 quarters
|
|
13
BioMarin Pharmaceuticals
BMRN
$10.7B
| $7.84M | 3.44% |
92,737
+2,785
| +3% | +$210K |
2018 Q1
7 quarters
|
|
14
UroGen Pharma
URGN
$1.88B
| $7.26M | 3.19% |
217,686
-107,699
| -33% | -$2.94M |
2019 Q1
3 quarters
|
|
|
ARNA
15
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.47M | 2.84% |
+142,400
| New | +$6.73M |
2019 Q4
0 quarters
|
|
|
ALBO
16
DELISTED
Albireo Pharma Inc
ALBO
| $6.28M | 2.76% |
247,178
-5,322
| -2% | -$106K |
2018 Q3
5 quarters
|
|
|
17
Envista
NVST
$3.67B
| $4.89M | 2.15% |
+165,000
| New | +$4.69M |
2019 Q4
0 quarters
|
|
18
Personalis
PSNL
$1.69B
| $4.43M | 1.95% |
406,673
+291,459
| +253% | +$3.03M |
2019 Q2
2 quarters
|
|
|
19
AnaptysBio
ANAB
$1.39B
| $3.82M | 1.68% |
+234,823
| New | +$5.55M |
2019 Q4
0 quarters
|
|
20
Immunovant
IMVT
$5.85B
| $3.57M | 1.57% |
+224,702
| New | +$2.52M |
2019 Q4
0 quarters
|
|
|
21
Organogenesis Holdings
ORGO
$152M
| $2.97M | 1.3% |
+617,836
| New | +$3.92M |
2019 Q4
0 quarters
|
|
22
Evolus
EOLS
$495M
| $2.88M | 1.27% |
+236,939
| New | +$3.34M |
2019 Q4
0 quarters
|
|
23
Gyre Therapeutics
GYRE
$709M
| $2.67M | 1.17% |
52,253
-22,168
| -30% | -$929K |
2018 Q3
5 quarters
|
|
|
SBBP
24
DELISTED
Strongbridge Biopharma plc.
SBBP
| $2.63M | 1.15% |
1,258,224
-1,256,848
| -50% | -$2.41M |
2018 Q3
5 quarters
|
|
25
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.6M | 1.14% |
200,000
-208,958
| -51% | -$2.39M |
2019 Q3
1 quarter
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2019 Portfolio in Review
As of Q4 2019, Prosight Management held 49 positions worth $228M, up 26% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Prosight Management's Q4 2019 filing shows 15 new, 12 increased, 11 reduced and 11 closed positions. Its largest new stake was AnaptysBio: 234,823 shares worth $3.82M. The largest sale was Bristol-Myers Squibb, an estimated $17M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Industrials.
- Prosight Management's largest Q4 2019 buy was AnaptysBio: 234,823 shares worth $3.82M.
- Prosight Management added most to Arena Pharmaceuticals Inc in Q4 2019, an estimated $7.8M increase.
- Prosight Management's biggest Q4 2019 reduction was Bristol-Myers Squibb, cutting an estimated $17M.
- Prosight Management fully exited Hanger Inc. in Q4 2019, selling an estimated $8.05M.
- Prosight Management's ten largest holdings make up 59% of its $228M portfolio in Q4 2019.
- Prosight Management opened 15 new positions and closed 11 in Q4 2019.
- Prosight Management's portfolio value rose 26% quarter-over-quarter to $228M.
Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.